natgillin/translations-raw huggingface dataset:
Thus, Ig-like domains have more structural than sequence similarities. 
Prema tome, Ig-slične domene imaju više sličnosti na razini strukutre nego na razini sekvencije.
Alternate Sidechain Coupling Reaction As illustrated above in the second reaction step of the alternative process of forming 7,9 acetal linked analogs of 9,10-aa OH taxanes, the C7,C10 di-CBZ 10-deacetylbaccatin III of Formula 35 was coupled with a sidechain of Formula 36 to form Formula 37. 
Kao što je gore prikazano u drugom koraku reakcije alternativnog postupka formiranja 7,9 acetalno povezanih analoga 9,10-aa OH taksana, C7, C10 di-CBZ 10-deacetilbakatin III formule 35 je bio spojen s bočnim lancem formule 36 da bi se formirala formula 37.
A compound selected from Compound 32 and Compound 33: or a pharmaceutically acceptable salt thereof. 
Spoj naznačen time da se bira od spoja 32 i spoja 33:
or a pharmaceutically acceptable salt or ester, thereof; wherein: 
Formula i ili njegova farmaceutski prihvatljiva sol ili ester; naznačen time, da:
1, where all walls of the box with additional walls 21 are presented, whereas said additional walls 21 serve the purpose of joining the elements which are arranged at right angles against each other, yet are not adjacent in the blank. 
1 gdje su prikazani svi zidovi kutije sa dodatnim zidovima 21, a navedeni zidovi 21 služe za spajanje elemenata koji su smješteni u desnim kutovima jedan nasuprot drugog, iako u shemi ne graniče.
In some embodiments, the dibenzenesulfonate salt has an X-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at about 15.0, 16.3, 18.3, 20.2, 23.8, and 4.9. 
Sol prema zahtjevu 6, naznačen time da ima uzorak difrakcije X-zraka na prahu koji obuhvaća karakteristične vrške izražene u stupnjevima 20 kod 15.0, 16.3, 18.3, 20.2, 23.8, 14.9.
A pharmaceutical composition comprising the antibody of any one of claims 1-11 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 4 ili 12 do 17, ili koje se proizvodi putem postupka prema zahtjevu 11, te farmaceutski prihvatljiv nosač.
According to a further embodiment of the present invention, provision is made for an edge region of the filter element which projects in the direction of the filling side to move in the direction of the capsule base when the central region is spaced apart from the capsule base during the third method step. 
Postupak za proizvodnju napitka upotrebom kapsule s porcijom (1) prema jednom od prethodnih zahtjeva, naznačen time da se u prvom koraku postupka osigurava kapsula s porcijom (1), naznačen time da je u drugom
If a mixture of polymorphic forms is used as a medicament great drawbacks are associated therewith as compared with a pure polymorphic form. 
Ukoliko se smjesa polimorfnih obika rabi kao lijek s tim su povezani veliki nedostaci u usporedbi s čistim polimorfnim oblicima.
The method of clause 5, wherein the unscheduled media item is selected for output in said programme slot according to one or more constraints associated with one or more media items allocated to at least one other programme slot. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se neraspoređenu medijsku točku bira za izlaženje u navedenoj rupi prema jednom ili više ograničenja povezanih s jednom ili više medijskih točaka na rasporedu za izlaženje u najmanje jednoj drugoj rupi u programu.
A pharmaceutical composition suitable for the oral treatment of multiple sclerosis consisting of dimethylfumarate and one agent selected from teriflunomide, fingolimod and laquinimod as active ingredients and one or more pharmaceutically acceptable excipients. 
Kombinacija za uporabu za oralno liječenje multiple skleroze koja se sastoji od dimetilfumarata i lakvinimoda kao djelatnih sastojaka i jedne ili više farmaceutski prihvatljivih pomoćnih tvari, naznačena time što je kombinacija za primjenu dva puta dnevno, te pri čemu kombinacija sadrži:
System for adapting an internal combustion engine to be powered by gaseous fuel in gas phase and by gaseous fuel in liquid phase at the same time, comprising at least one cylinder and at least one liquid fuel injector (16) for injecting liquid fuel directly into the at least one cylinder, wherein the system comprises: 
PATENTNI ZAHTJEVI Sustav za prilagodbu motora s unutarnjim izgaranjem pogonjenog plinovitim gorivom u plinskoj fazi i plinovitim gorivom u tekućoj fazi u isto vrijeme, sadržeći najmanje jedan cilindar i najmanje jedan ubrizgač tekućeg goriva (16) za izravno ubrizgavanje tekućeg goriva u najmanje jedan cilindar, pri čemu sustav obuhvaća:
The flask was loaded with intermediate 2 (15.10 g,) and 2-chloroethanol (17.7 g, 218 mmol) and stirred with heating (90° C.) for 20 hours. 
Posuda je napunjena Intermedijerom 2 (15.10 g) i 2-kloroetanolom (17.7 g, 218 mmol) i smjesa je miješana uz zagrijavanje (90%C) 20 sati.
The method of claim 1, wherein the nerve fibers are nerve fibers of the skin and the administration of the polypeptide results in skin reinnervation. 
Polipeptid za uporabu kao u zahtjevima 2 ili 3, naznačen time, što živčana vlakna jesu živčana vlakna kože, a primjena polipeptida za rezultat ima ponovnu inervaciju kože.
As used herein, an antibody that “blocks the inhibitory effect of sclerostin in a cell based wnt signaling assay” is intended to refer to an antibody that restores wnt induced signaling in the presence of sclerostin in a cell-based super top flash (STF) assay with an IC50 less than 1 mM, 100 nM, 20 nM, 10 nM or less. 
4. Protutijelo ili njegov dio koji veže antigen prema zahtjevu 3, naznačeno time da navedeno protutijelo ili njegov dio koji veže antigen ima vrijednost IC5, manju od 1 uM, poželjno manju od 100 nM i poželjnije manju od 20 nM kako je mjereno sa staničnim testom Wnt signalizacije kod HEK293 staničnih linija u prisutnosti sklerostina.
An anti-tumor agent comprising a compound according to Claim 1, a salt thereof or a hydrate of the foregoing. 
Anti-tumorsko sredstvo naznačeno time da sadrži spoj prema zahtjevu 1, njegovu sol ili hidrat navedenog.
The compound as recited in Claim 1, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
VBP15 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
A compound or pharmaceutically acceptable salt thereof, according to claim 1, wherein R1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl. 
Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time što R1 je furanil, tiofenil, pirazolil, imidazolil, tiazolil, oksazolil, piridinil, piridazinil, pirimidil, ili pirazinil.
The method of manufacturing the non-aqueous veterinary pharmaceutical composition of claim 6, including preparing the at least one oily vehicle by either (i) providing the at least one oily vehicle, or (ii) mixing the at least one oily vehicle and a surfactant in a container to form a homogenous oil mixture: and 
Postupak proizvodnje pripravka prema bilo kojem od patentnih zahtjeva 1 do 6 naznačen time što sadrži korake: a) pripremanje uljaste smjese miješanjem ulja i surfaktanta u posudi da nastane homogena smjesa ulja: i b) dispergiranje penetamat hidrojodida u uljastom nosaču.
The pharmaceutical composition of claim 6, wherein RNAi agent is to be administered in an unbuffered solution, wherein said unbuffered solution is preferably saline or water; or with a buffer solution, wherein said buffer solution preferably comprises acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof, wherein it is particularly preferred that said buffer solution is phosphate buffered saline (PBS). 
Farmaceutski pripravak prema zahtjevu 6. naznačen time da se RNA1 sredstvo primjenjuje (a) une puferiranoj otopini, pri čemu je navedena ne puferirana otopina poželjno fiziološka otopina ili voda; ili (b) sa puferiranom otopinom, pri čemu navedena puferirana otopina poželjno sadrži acetat, citrat, prolamin, karbonat, ili fosfat ili bilo koju njihovu kombinaciju, pri čemu je naročito poželjno da je navedena puferirana otopina fiziološka otopina s fosfatnim puferom (PBS).
Most preferably, when step (d) is performed at least twice, all rinses except the last one are performed with Purified Water, and the last rinse is performed with Water For Injection. 
Još poželjnije je da se korak (d) provodi najmanje dva puta, pri čemu se svi koraci ispiranja, osim zadnjeg, provode s pročišćenom vodom, a zadnji se provodi s vodom za injektiranje.
A product comprising (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease as defined in claim 10 or 11. 
Proizvod koji sadrži (a) B2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 13 do 6 i (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti kako je definirana u patentnom zahtjevu 10 ili 11.
Thus the present invention is directed to a method for synthesizing N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide and the mesylate salt thereof according to the following steps: Step A: Reacting compound A of the following general formula A* 
PATENTNI ZAHTJEVI 1. Metoda za sintetiziranje N-[S-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)feniljacetamida prema sljedećim koracima: Korak A: reakcija tvari A sljedeće opće formule A*
The statin drugs disrupt the synthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme ("HMG-CoA reductase"). 
Statini zaustavljaju sintezu kolesterola 1 ostalih sterola u jetri kompetitivnom inhibicijom enzima 3-hidroksi-3-metil-glutaril-koenzim A reduktaze ("HMG-CoA reduktaza").
sawing said at least one main micro trench in said area through said first layer (L1) and into said second layer (L2) using a sawing machine comprising a diamond saw blade arranged for up-cut rotational direction; said sawing machine further comprising a stabilizing device, during operation positioned immediately behind said diamond saw blade in said micro trench and having a front part with a shape complementary to the shape of said diamond saw blade; wherein said diamond saw blade and said stabilizing device are arranged so that their respective working depths may be adjusted in order to adjust a laying depth; wherein said working depth for said stabilizing device is less than said working depth for said diamond saw blade; 
- rezanja navedenog najmanje jednog glavnog mikro-rova u navedenom području kroz navedeni prvi sloj (L1) i u navedeni drugi sloj (L2) pomoću stroja za piljenje koji sadrži dijamantnu oštricu pile razmještenu sa smjerom vrtnje rezanja prema gore; navedeni stroj za piljenje nadalje obuhvaća stabilizirajuću napravu, tijekom upotrebe smještenu odmah iza navedene dijamantne oštrice pile u navedenom mikro-rovu i imajući prednji dio oblika komplementarnog obliku navedene dijamantne oštrice pile; pri čemu su navedena dijamantna oštrica pile i navedena stabilizirajuća naprava postavljene tako da se njihove odgovarajuće radne dubine mogu podesiti kako bi se podesila dubina polaganja; pri čemu je navedena radna dubina za navedenu stabilizirajuću napravu manja od navedene radne dubine za navedenu dijamantnu oštricu pile;
represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, or a trifluoromethyl group; 
Ro predstavlja vodikov atom, halogeni atom, alkilnu skupinu koja ima 1 do 6 ugljikovih atoma, ili trifluorometil skupinu;
In at least one embodiment, a method is provided for treating the following disorders: metabolic syndrome, macular degeneration, Omega-3 deficiency, cognitive impairment, including as a result of surgery or traumatic brain injury (such as, for example, resulting from a concussion), major depression, suicide, post-partum depression, inflammation, primary sclerosing cholangitis, borderline personality disorder in women, breast cancer, non-alcoholic fatty acid liver disease, and improvement in cognition and behavior in children. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u liječenju bolesti ili poremećaja kojeg se bira između: metaboličkog sindroma, degeneracije makule, nedostatka omega-3 masnih kiselina, kognitivnog poremećaja, uključujući posljedicu kirurškog zahvata ili traumatske ozljede mozga (poput, primjerice, posljedice potresa mozga), velike depresije, samoubojstva, poslijeporođajne depresije, upale, primarnog sklerotizirajućeg kolangitisa, graničnog poremećaja osobnosti kod žena, raka dojke, nealkoholne bolesti masne jetre, te poboljšavanja kognitivnih funkcija i ponašanja kod djece.
Potassium carbonate (9.55 g, 0.069 mole) is added and the reaction mixture is heated at 120°C for 1.5 h. Reaction mixture is concentrated under vacuum, water (50 mL) is added to the residue and extracted with ethyl acetate (3x30 mL). 
Doda se kalijev karbonat (9,55 g, 0,069 mol), a reakcijsku smjesu grije 1,5 sati na 120 *C. Reakcijsku smjesu koncentrira se u vakuumu, ostatku se doda voda (50 ml), te ekstrahira etil-acetatom (3 x 30 ml).
a variable heavy domain comprising SEQ ID NO:160; and 
varijabilnu tešku domenu koja sadrži SEQ ID NO: 160; i
or pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak naznačen time što sadrži terapeutski učinkovitu količinu spoja kako je definiran u bilo kojem od zahtjeva 1 do 8 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
adding a solution of FeCl3 to the solution of (ii) at a temperature within the range of from 10 to 30°C; preferably, the amount of FeCl3 is in the range of from 30% wt.-% to 120% wt.-% of the amount of glucose syrup. 
(lii)(a) dodavanje otopine FeC13 otopini u skladu s korakom (ii) temperature unutar raspona od 10 do 30"C; količina FeC13 raspona od 30% masenog udjela do 120% masenog udjela količine glukoznog sirupa.
The process of claim 5 wherein the bacterial saccharide is Haemophilus influenzae b (Hib) polysaccharide or oligosaccharide. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što bakterijski saharid je polisaharid ili oligosaharid iz bakterije Haemophilus influenzae b (Hib).
The compound of Claim 1, where R2 is -CH2OH and R3 is H. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R2 -CH2OH i R3 je H.
In one embodiment, the mouse comprises a B cell that expresses a binding protein that specifically binds an antigen of interest, wherein the binding protein comprises a light chain derived from a human Vk1-39/Jk5 rearrangement or a human Vk3-20/Jk1 rearrangement, and wherein the cell comprises a rearranged immunoglobulin heavy chain gene derived from a rearrangement of human gene segments selected from a VH2-5, VH3-23, VH3-30, VH 4-39, VH4-59, and VH5-51 gene segment. 
(b) miš eksprimira laki lanac humani imunoglobulina koji je zajednički za više humanih teških lanaca, zajednički laki lanac potječe iz navedenog genskog odsječka varijabilne regije lakog lanca humanog imunoglobulina; (c) miš sadržava B-stanicu koja eksprimira protutijelo koje se specifično veže na antigen od interesa, pri čemu protutijelo sadržava navedeni zajednički laki lanac 1 teški lanac imunoglobulina dobivene preuređenjem genskih odsječaka varijabilne regije teškog lanca o (Vag) humanog imunoglobulina odabranih iz skupine koja se sastoji od odsječaka gena Vr2-5, Vu3-23, Vr3-30, Vu4-59 i Vn5-51 1
A sunscreen comprising the composition according to claim 1 and at least one agent acting as filter for UV-B and UV-A rays. 
Krema za sunčanje, naznačena time što sadrži pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 51 najmanje jedno sredstvo koje djeluje kao filtar za UV-B i UV-A zrake.
R4/R4' are independently from each other hydrogen, C1-4-alkyl, CH2-C1-4-alkoxy or may form together with the carbon atom to which they are attached a C3-C6-cycloalkyl; 
/R4' su međusobno neovisno vodik, C1-4-alkil, CH2-C1-4-alkoksi ili zajedno s atomom ugljika na kojega su priključeni, mogu tvoriti -6-cikloalkil;
The pharmaceutical composition according to claim 1, wherein the anti-HIV agent is an antiviral selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors. 
Spoj formule I prema patentnom zahtjevu 1, gdje je spoj izabran iz grupe koju čine: [image] [image] i njegove farmaceutski prihvatljive soli. Spoj formule I prema patentnom zahtjevu 1 koji je [image]
performing intra prediction on the current block using a prediction mode, indicated by the mode index, among the candidate intra prediction modes included in the candidate list, wherein, the candidate intra prediction modes include a planar mode, when the intra prediction modes of the left block and the upper block are equal to each other and the intra mode of the left block is the DC mode. 
- < provođenje unutrašnjeg predviđanja trenutnog bloka uz korištenje načina predviđanja, koji je određen s indeksom načina, između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata, naznačen time da popis kandidata načina unutrašnjeg predviđanja sadrži ravninski način, kada su načini unutrašnjeg predviđanja lijevog bloka 1 gornjega bloka međusobno jednaki i unutrašnji način lijevog bloka je DC način.
In one specific aspect of the invention the compound of formula I or a pharmaceutically acceptable salt thereof and doxorubicin are administered to the mammal. 
Spoj u kombinaciji za uporabu prema zahtjevu 1, naznačen time, da se spoj formule Ia i abirateron primjenjuju odvojeno.
the system comprises a plurality of layers containing a nitrite; and/or 
(a) sustav sadrži množinu slojeva koji sadrže nitrit; i/ili
The composition of claim 6 wherein the matrix forming polymer is dextran, polyvinylpyrrolidone (PVP), ionic or neutral polysaccharides, polyacrylic acid, poly methacrylic acid derivatives or polyvinyl alcohol. 
Pripravak prema zahtjevu 6 naznačen time da polimer koji tvori matricu je dekstran, polivinilpirolidon (PVP), ionski ili neutralni polisaharidi, poliakrilna kiselina, derivati poli metakrilne kiseline ili polivinil alkohol.
A device to handle sensitive data comprising at least one first integrated circuitry to form a first trust zone and at least one second integrated circuitry to form a second trust zone, wherein the second integrated circuitry comprises: a persistent memory area located within said second trust zone to store the sensitive data; 
Uređaj za rukovanje osjetljivim podacima koji sadrži najmanje jedan prvi integrirani krug (10), namijenjen stvaranju prvog područja povjerenja, i najmanje jedan drugi integrirani krug (20), gdje navedeni drugi integrirani krug (20) stvara drugo područje povjerenja, naznačen time što sadrži:
the tyrosine at position 11 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, or W. 
tirozin na položaju 11 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V ili W.
A package including a topical composition as defined in claim 6, said package comprising a container and instructions for use of the topical composition for treating or preventing rosacea-induced redness. 
Topička kompozicija za uporabu prema patentnom zahtjevu 3, naznačeno time da je navedena kompozicija uključena u pakiranje, navedeno pakiranje sadrži spremnik i upute za uporabu topičke kompozicije za liječenje rosaceom induciranog crvenila.
or a pharmaceutically acceptable salt thereof. 
ili njegova farmaceutski prihvatljiva sol, pri čemu:
Antibacterial agent under p. 1-5, characterized in that in certain acceptable concentrations of components it is a non-medicinal agent. Method of producing the antibacterial agent under p. 1, comprising complexation reaction of carbohydrates and proteins with metal salts, and intercalation of iodine into complex at ionic strength from 5·10-4 to 15, characterized in that introduction of immunotropic proteins is carried out as an individual stage after iodine intercalation of 5 - 95%. 
Postupak proizvodnje antibakterijskog sredstva prema bilo kojem od zahtjeva 1 ili 2, naznačen time, da obuhvaća reakciju strukturiranja kompleksa ugljikohidrata i proteina s metalnim solima i umetnutim jodom u takav kompleks, uz ionsku snagu od 5.10-4 do 15, pri čemu se uvođenje navedenih proteina vrši kao pojedinačna faza nakon prethodnog strukturnog umetanja od 5 do 95% joda.
Example of embodiment of the invention 
Broj objave europskog patenta:
The composition for the use of claim 13 or 14, wherein the first heterologous antigen and the second heterologous antigen are the same antigen. 
Pripravak za upotrebu u skladu s patentnim zahtjevom13 ili 14, naznačen time, da su prvi heterologni antigen i drugi heterologni antigen isti antigen.
Machine according to claim 7, wherein said tubular boarding forms (5) are carried by a common conveyor, preferably shaped in the form of a carousel (3) rotating around an axis that is preferably parallel to the longitudinal axes of the tubular boarding forms (5). 
Stroj u skladu s patentnim zahtjevom 7, naznačen time, da su navedeni cjevasti kalupi za izravnavanje (5) poduprti uobičajenom transportnom trakom, po mogućnosti kružnog oblika (3) koja se okreće oko osi koja je poželjno paralelna s uzdužnim osima cjevastih kalupa za izravnavanje (5).
A pharmaceutical composition comprising a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1 together with a pharmaceutically accepted carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 27, zajedno s farmaceutski prikladnim nosačem ili pomoćnim sredstvom.
Compound 48 was obtained as a dark solid from compound 47 by method F. 
Spoj 48 se dobiva kao tamna krutina iz spoja 47 pomoću postupka F.
The method of claim 1, wherein when the left intra prediction mode is a planar mode and the above intra prediction mode is the planar mode, the MPM group includes a DC mode, the planar mode and the vertical mode. 
Postupak prema Zahtjevu 1, gdje kada je lijevi intrapredikcijski režim planarni režim, i gdje kada je gornji intrapredikcijski režim planarni režim, MPM grupa sadrži DC režim, planarni režim i vertikalni režim.
for use in a method for treatment of a disease selected from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis, or 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 18, ili njegova farmaceutski prihvatljiva sol, za upotrebu u postupku liječenja bolesti odabrane od Amiotrofne Lateralne Skleroze (ALS), Spinalne Mišićne Atrofije (SMA) i miastenije gravis.
The isolated yield of final product 2-3 was 89%. 
Izolirani prinos konačnog produkta 2-3 iznosio je 89%.
Drugs for delivery using lozenges of the invention may optionally be in the form of a pharmaceutically acceptable salt. 
Lijekovi za primjenu uporabom tableta prema izumu mogu izborno biti u obliku farmaceutski prihvatljive soli.
As shown in Figure 2C, the cap 200 may be affixed to the opening of the container 101 by threads 204 . 
Kako je prikazano na Slici 2C, poklopac 200 može biti pričvršćen na otvor posude 101 preko navoja 204.